A Phase II Open-Label Extension Study of Patients Previously Enrolled in Study GA29350 to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Rheumatoid Arthritis

Trial Profile

A Phase II Open-Label Extension Study of Patients Previously Enrolled in Study GA29350 to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Rheumatoid Arthritis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs GDC 0853 (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Genentech
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 03 Apr 2017 Status changed from active, no longer recruiting to recruiting.
    • 29 Mar 2017 Planned End Date changed from 1 Oct 2019 to 24 Jul 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top